5YXW

Crystal structure of the prefusion form of measles virus fusion protein


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.776 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.202 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structures of the prefusion form of measles virus fusion protein in complex with inhibitors.

Hashiguchi, T.Fukuda, Y.Matsuoka, R.Kuroda, D.Kubota, M.Shirogane, Y.Watanabe, S.Tsumoto, K.Kohda, D.Plemper, R.K.Yanagi, Y.

(2018) Proc. Natl. Acad. Sci. U.S.A. 115: 2496-2501

  • DOI: 10.1073/pnas.1718957115
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Measles virus (MeV), a major cause of childhood morbidity and mortality, is highly immunotropic and one of the most contagious pathogens. MeV may establish, albeit rarely, persistent infection in the central nervous system, causing fatal and intracta ...

    Measles virus (MeV), a major cause of childhood morbidity and mortality, is highly immunotropic and one of the most contagious pathogens. MeV may establish, albeit rarely, persistent infection in the central nervous system, causing fatal and intractable neurodegenerative diseases such as subacute sclerosing panencephalitis and measles inclusion body encephalitis. Recent studies have suggested that particular substitutions in the MeV fusion (F) protein are involved in the pathogenesis by destabilizing the F protein and endowing it with hyperfusogenicity. Here we show the crystal structures of the prefusion MeV-F alone and in complex with the small compound AS-48 or a fusion inhibitor peptide. Notably, these independently developed inhibitors bind the same hydrophobic pocket located at the region connecting the head and stalk of MeV-F, where a number of substitutions in MeV isolates from neurodegenerative diseases are also localized. Since these inhibitors could suppress membrane fusion mediated by most of the hyperfusogenic MeV-F mutants, the development of more effective inhibitors based on the structures may be warranted to treat MeV-induced neurodegenerative diseases.


    Organizational Affiliation

    Division of Structural Biology, Medical Institute of Bioregulation, Kyushu University, 812-8582 Fukuoka, Japan.,Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303.,Department of Virology, Faculty of Medicine, Kyushu University, 812-8582 Fukuoka, Japan; takaoh@virology.med.kyushu-u.ac.jp yyanagi@virology.med.kyushu-u.ac.jp.,Department of Virology, Faculty of Medicine, Kyushu University, 812-8582 Fukuoka, Japan.,Department of Bioengineering, School of Engineering, The University of Tokyo, 113-8656 Tokyo, Japan.,Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 108-8639 Tokyo, Japan.,Biostructural Mechanism Laboratory, RIKEN SPring-8 Center, 679-5148 Hyogo, Japan.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
glycoprotein F2
A
94Measles virus (strain Ichinose-B95a)Mutation(s): 0 
Gene Names: F
Find proteins for Q786F3 (Measles virus (strain Ichinose-B95a))
Go to UniProtKB:  Q786F3
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
glycoprotein F1,measles virus fusion protein
B
419Measles virus (strain Ichinose-B95a)Mutation(s): 0 
Gene Names: F
Find proteins for Q786F3 (Measles virus (strain Ichinose-B95a))
Go to UniProtKB:  Q786F3
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NAG
Query on NAG

Download SDF File 
Download CCD File 
A
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.776 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.202 
  • Space Group: I 21 3
Unit Cell:
Length (Å)Angle (°)
a = 167.389α = 90.00
b = 167.389β = 90.00
c = 167.389γ = 90.00
Software Package:
Software NamePurpose
PHENIXphasing
Cootmodel building
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
MEXTJapan17K19562
MEXTJapan24115005
AMEDJapan17fm0208022h0001
NIH/NIAIDUnited StatesAI071002
NIH/NIAIDUnited StatesHD079327

Revision History 

  • Version 1.0: 2018-02-21
    Type: Initial release
  • Version 1.1: 2018-03-07
    Type: Database references
  • Version 1.2: 2018-03-21
    Type: Database references